阿立哌唑与利培酮治疗精神分裂症阴性症状的疗效和安全性对照观察
详细信息 查看官网全文
- 英文论文题名：Efficacy and safety of aripiprazole in treating negative symptoms of schizophrenia
- 论文作者：贾天成 ; 邵益峰
- 英文论文作者：Jia Tiancheng ; Department of psychiatry ; the 4th People's Hospital of Jiande
- 年：2014
- 作者机构：浙江省建德市第四人民医院精神科;
- 论文关键词：阿立哌唑 ; 利培酮 ; 精神分裂症 ; 阴性症状 ; 疗效 ; 安全性
- 英文论文关键词：Aripiprazole ; Schizophrenia ; Negtive symptoms ; Eefficacy ; Safety
- 会议召开时间：2014-11-20
- 会议录名称：2014浙江省医学会精神病学分会学术年会、浙江省医师协会精神科医师分会第七届年会论文汇编
- 语种：中文
- 分类号：R749.3
- 学会代码：ZJKX
- 会议名称：2014浙江省医学会精神病学分会学术年会、浙江省医师协会精神科医师分会第七届年会
- 会议地点：中国浙江湖州
- 主办单位：浙江省医学会精神病学分会（The Society of Psychiatry ; ZJMA）、浙江省医师协会精神科医师分会
- 学会名称：浙江省科学技术协会
- 页数：4
- 文件大小：329k
- 原文格式：O
- 会议级别：地方
摘要
目的探讨阿立哌唑治疗精神分裂症阴性症状的疗效和安全性。方法 80名精神分裂症患者随机分入研究组(阿立哌唑治疗)和对照组(利培酮治疗),每组40例,在治疗前及治疗的2、4、8周末分别采用潘氏阳性与阴性症状量表(PANSS)和阴性症状评定量表(SANS)评分,并记录治疗期间发生的不良反应。结果两组患者治疗后的PANSS量表总分及SANS总分均明显降低(P<0.05),但同一时期,两组患者间的PANSS量表总分及SANS量表评分差异无统计学意义(P>0.05)。在治疗后第4、8周,研究组患者"思维贫乏"及"意志缺乏"的因子分较对照组明显下降(P<0.05),而对照组患者"兴趣/社交缺乏"的评分则明显低于同期的研究组患者(P<0.05)。阿立哌唑不良反应发生率小于利培酮(P<0.05)。结论阿立哌唑与利培酮均能改善精神分裂症患者的阴性症状,且总体疗效相似,但阿立哌唑更善于改善患者的情感与认知症状,而利培酮则对患者的情感与行为症状更有效。阿立哌唑的用药安全性总体上优于利培酮。
Objective To explore the efficacy and safety of aripiprazole in treating negtive symptoms of schizophrenia.Methods80 patients with schizophrenia were randomly assigned to the experimental group(treated with aripiprazole) and the control group(treated with risperidone),40 cases in each group.Positive and Negative Syndrome Scale(PANSS) and Scale for Assessment of Negative Symptoms(SANS) were used before treatment,and at the weekend of 2nd,4th,8th after treatment respectively.Results The scores of PANSS and SANS in both two groups were decreased in comparison with pretreatment(P<0.05),but there s no significant difference bwtween the two groups(P > 0.05).At the 4th,8th weekends of post-treatment,the scores of "poverty of thought" and "abulia" in experimental group were decreased in comparison with the control group(P<0.05),while score of "lack of social or interest" was higher than the control group(P > 0.05).The incidence of adverse effect in experimental group was less than the control group(P<0.05).Conclusion Both aripiprazole and risperidone can improve the negtive symptoms of schizophrenia with the similar efficacy,however,aripiprazole is adept in treating the symptoms of affection and cognition,compared with the advantage of risperidone in treating the symptoms of affection and behavior,aripiprazole is generally safer than risperidone.
Objective To explore the efficacy and safety of aripiprazole in treating negtive symptoms of schizophrenia.Methods80 patients with schizophrenia were randomly assigned to the experimental group(treated with aripiprazole) and the control group(treated with risperidone),40 cases in each group.Positive and Negative Syndrome Scale(PANSS) and Scale for Assessment of Negative Symptoms(SANS) were used before treatment,and at the weekend of 2nd,4th,8th after treatment respectively.Results The scores of PANSS and SANS in both two groups were decreased in comparison with pretreatment(P<0.05),but there s no significant difference bwtween the two groups(P > 0.05).At the 4th,8th weekends of post-treatment,the scores of "poverty of thought" and "abulia" in experimental group were decreased in comparison with the control group(P<0.05),while score of "lack of social or interest" was higher than the control group(P > 0.05).The incidence of adverse effect in experimental group was less than the control group(P<0.05).Conclusion Both aripiprazole and risperidone can improve the negtive symptoms of schizophrenia with the similar efficacy,however,aripiprazole is adept in treating the symptoms of affection and cognition,compared with the advantage of risperidone in treating the symptoms of affection and behavior,aripiprazole is generally safer than risperidone.
引文
[1]沈渔邮.精神病学[M].5版.北京:人民卫生出版社,2009:508.
[2]李辉,陈孝芬.阿立哌唑与利培酮治疗首发精神分裂症对照研究[J].临床心身疾病杂志,2010,16(2):120.
[3]中华医学会精神病学分会.中国精神障碍分类与诊断标准(CCMD-3)[M].3版.济南:山东科学技术出版社,2001:87-88.
[4]汪向东,王希林,马弘.心理卫生评定量表手册[M].增订版.北京:中国心理卫生杂志,1999:26-27.
[5]张淑芳,马闯胜,邱松伟.齐拉西酮联合氟西汀治疗精神分裂症阴性症状对照研究[J].临床心身疾病杂志,2009,15(3):224.
[6]童建明,杨正春.阿立哌唑与利培酮治疗精神分裂症对照研究[J].临床心身疾病杂志,2007,13(1):7.
[7]蔡伟,赵莉莉.阿立哌唑与利培酮治疗首发精神分裂症对照研究[J]临床心身疾病杂志,2009,15(3):23.
[8]孙文生,玄吉龙.阿立哌唑与利培酮治疗精神分裂症对照研究[J].临床精神医学杂志,2009,19(1):27-28.
[9]李莹,宋新勤,曹红军,等.阿立哌唑与利培酮治疗女性首发精神分裂症对照研究[J].临床心身疾病杂志,2010,16(3):235.
[2]李辉,陈孝芬.阿立哌唑与利培酮治疗首发精神分裂症对照研究[J].临床心身疾病杂志,2010,16(2):120.
[3]中华医学会精神病学分会.中国精神障碍分类与诊断标准(CCMD-3)[M].3版.济南:山东科学技术出版社,2001:87-88.
[4]汪向东,王希林,马弘.心理卫生评定量表手册[M].增订版.北京:中国心理卫生杂志,1999:26-27.
[5]张淑芳,马闯胜,邱松伟.齐拉西酮联合氟西汀治疗精神分裂症阴性症状对照研究[J].临床心身疾病杂志,2009,15(3):224.
[6]童建明,杨正春.阿立哌唑与利培酮治疗精神分裂症对照研究[J].临床心身疾病杂志,2007,13(1):7.
[7]蔡伟,赵莉莉.阿立哌唑与利培酮治疗首发精神分裂症对照研究[J]临床心身疾病杂志,2009,15(3):23.
[8]孙文生,玄吉龙.阿立哌唑与利培酮治疗精神分裂症对照研究[J].临床精神医学杂志,2009,19(1):27-28.
[9]李莹,宋新勤,曹红军,等.阿立哌唑与利培酮治疗女性首发精神分裂症对照研究[J].临床心身疾病杂志,2010,16(3):235.